Cancer Care Engineering of Colorectal Cancer - OMICs Pilot Study
- Perform metabolomic, lipidomic, glycoproteomic, proteomic, and genomic (OMIC) profiling
using blood and tissue samples from patients with colorectal cancer (CRC) or colorectal
adenomatous polyps and from patients without polyps.
- Create an OMIC profile to predict the risk of CRC based on differences observed between
patients with CRC, patients with colorectal adenomatous polyps, and patients without
- Create an OMIC profile to predict response and toxicity to specific chemotherapies,
biological therapies, and radiotherapy for CRC.
- Utilize a novel knowledge discovery tool (BioMap) based on literature mining and, in
the future, utilize the results of the OMIC analyses to identify interactive molecular
pathways that underlie the development and progression of CRC.
OUTLINE: Patients with locally advanced or metastatic colorectal cancer are stratified
according to treatment (first-line chemotherapy with fluorouracil [5-FU]/oxaliplatin or
5-FU/irinotecan vs second- or third-line chemotherapy with irinotecan only vs biological
therapy with bevacizumab vs biological therapy with cetuximab vs radiotherapy).
Blood and tissue samples are collected periodically for laboratory studies. Samples are
analyzed for metabolomics by nuclear magnetic resonance, gas chromatography, liquid
chromatography, and mass spectrometry; lipidomics, proteomics, and glycoproteomics by liquid
chromatography and mass spectrometry; and genomics (single nucleotide polymorphism
biomarkers) by PCR. Vitamin D status is also assessed.
Patients complete diet-history and lifestyle questionnaires at baseline and once a year for
2 years. Healthy volunteers complete these questionnaires only at baseline.
After completion of study, patients are followed every 3 months for 2 years, every 6 months
for 3 years, and then annually thereafter. Healthy volunteers are not followed after study
Observational Model: Case Control, Time Perspective: Prospective
Metabolomic, lipidomic, glycoproteomic, proteomic, and genomic (OMIC) profiling
End of Study
Patrick J Loehrer, MD
Indiana University Melvin and Bren Simon Cancer Center
United States: Institutional Review Board
|Indiana University Melvin and Bren Simon Cancer Center||Indianapolis, Indiana 46202-5289|